Open AccessRAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
Author(s) -
Helden Erik J.,
Angus Lindsay,
Menkevan der Houven van Oordt C. Willemien,
Heideman Daniëlle A. M.,
Boon Eline,
Es Suzanne C.,
Radema Sandra A.,
Herpen Carla M. L.,
Groot Derk Jan A.,
Vries Elisabeth G. E.,
Jansen Maurice P. H. M.,
Sleijfer Stefan,
Verheul Henk M. W.
Publication year - 2019
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12550
Subject(s) - cetuximab , colorectal cancer , mutation , medicine , cancer research , kras , oncology , cancer , biology , gene , genetics
In metastatic colorectal cancer, RAS and BRAF mutations cause resistance to anti‐ EGFR therapies, such as cetuximab. Heterogeneity in RAS and BRAF mutations might explain nonresponse in a subset of patients receiving cetuximab. Analyzing mutations in plasma‐derived circulating tumor DNA (ct DNA ) could provide a more comprehensive overview of the mutational landscape as compared to analyses of primary and/or metastatic tumor tissue. Therefore, this prospective multicenter study followed 34 patients with metastatic colorectal cancer who were tissue‐tested as RAS wild‐type (exons 2–4) during routine work‐up and received third‐line cetuximab monotherapy. BRAF mutation status was also tested but did not exclude patients from therapy. At baseline and upon disease progression, cell‐free DNA (cf DNA ) was isolated for targeted next‐generation sequencing ( NGS ). At 8 weeks, we determined that patients had benefited from treatment. NGS of cf DNA identified three patients with RAS mutations not detected in tumor tissue during routine work‐up. Another six patients had a BRAF or rare RAS mutation in ct DNA and/or tumor tissue. Relative to patients without mutations in RAS / BRAF , patients with mutations at baseline had shorter progression‐free survival [1.8 versus 4.9 months ( P < 0.001)] and overall survival [3.1 versus 9.4 months ( P = 0.001)]. In patients with clinical benefit (progressive disease after 8 weeks), ct DNA testing revealed previously undetected mutations in RAS / BRAF (71%) and EGFR (47%), which often emerged polyclonally. Our results indicate that baseline NGS of ct DNA can identify additional RAS mutation carriers, which could improve patient selection for anti‐ EGFR therapies. Acquired resistance, in patients with initial treatment benefit, is mainly explained by polyclonal emergence of RAS , BRAF , and EGFR mutations in ct DNA .